Abstract Body

The Parkinson Progression Marker Initiative (PPMI) is a longitudinal, observational, multi-center study to assess progression of clinical outcomes, and imaging, biologic and genetic biomarkers of Parkinson’s disease (PD) progression. The PPMI study has established a robust clinical and biomarker dataset. PPMI has now expanded the number of participants across the PD continuum from prodromal to moderate PD and identify and explore the use of biomarkers to examine the underlying molecular pathobiology of PD, enable modeling of PD progression to identify data driven PD progression sub-sets, and inform studies testing PD therapeutics.

The PPMI prodromal cohort will enroll 2000 participants at high risk of developing PD during the next 3-5 years based on a staged risk paradigm. We plan to enroll approximately 100000 participants in to PPMI online, a customized online platform, to identify those at some risk using questionnaires followed by remote olfactory, genetic and digital testing. Those eligible will be further evaluated in clinic with DAT imaging and then if eligible, enrolled at PPMI study sites in a five-year comprehensive observational, longitudinal clinical study.

We will demonstrate proof of concept for this eligibility paradigm and will provide exploratory data identifying clinical subsets of PD that may predict disease progression. PPMI will expand the existing data set and biorepository already available from PPMI. he PPMI expansion has the potential to establish an algorithm for developing a prodromal PD cohort and to identify meaningful clinical and biomarker outcomes that could accelerate clinical trials of both manifest and prodromal PD.